News
-
Jazz Pharma receives FDA approval for rare veno occlusive disease
almost 8 years ago by Gerry Kennedy
Jazz Pharmaceuticals (NASDAQ: JAZZ) has announced that the US Food and Drug Administration (FDA) has granted marketing approval for Defitelio (defibrotide sodium) for the treatment of adult and paediatric patients with hepatic veno-occlusive disease. Also called sinusoidal obstruction syndrome (SOS), Defitelio is indicated for the treatment o...
Read More -
Sanofi and Regeneron meet endpoint in Phase III Praluent study
about 8 years ago by Gerry Kennedy
Praluent is a proproetin convertase subtilisin/kexin type 9 (or PCSK9) inhibitor that is being evaluated as a treatment in patients with an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH). With HeFH, cholesterol levels require chronic, weekly or bi-weekly apheresis therapy, which is a therapy where ...
Read More -
Sanders asks Treasury to block Pfizer and Allergan merger
about 8 years ago by Gerry Kennedy
Sanders asks Treasury to 'block' Pfizer and Allergan mergerBy Eric Palmer Sen. Bernie SandersIn between campaign stops, presidential candidate Sen. Bernie Sanders is finding time to keep pressure on the pharmaceutical industry. This time he is pushing the U.S. Treasury Department to try to stop Pfizer's ($PFE) $160 billion tax-avoiding merger wi...
Read More -
Doctors taking a shine to biosimilars by Eric Palmer
about 8 years ago by Gerry Kennedy
Doctors taking a shine to biosimilars as they get experience with themMarch 18, 2016 | By Eric Palmer Three years ago, doctors in Europe displayed grave doubts about using biosimilars instead of branded biologics on their patients. But after a couple of years of experience with a biosimilar of Merck's ($MRK) Remicade (infliximab) from Hospira an...
Read More -
Sanofi ($SNY) and Regeneron ($REGN), awaiting FDA approval for a potential blockbuster rheumatoid arthritis treatment, burnished the drug's profile with Phase III data showing it beat AbbVie's ($ABBV) top-selling Humira head to head.
about 8 years ago by Gerry Kennedy
Sanofi ($SNY) and Regeneron ($REGN), awaiting FDA approval for a potential blockbuster rheumatoid arthritis treatment, burnished the drug's profile with Phase III data showing it beat AbbVie's ($ABBV) top-selling Humira head to head. The treatment, sarilumab, is an antibody targeting the inflammation-related protein interleukin-6 to treat aut...
Read More